Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Chlorambucil Clear all
Completed Phase 3 Interventional Results available

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01724346
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Next-line ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
16
States / cities
Duarte, California • La Jolla, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

NCT00117598
View directory record Official record
Conditions
Lymphoma
Interventions
Temsirolimus (CCI-779), Investigator's choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

NCT01980875
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Chlorambucil, Obinutuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Santa Barbara, California • Santa Monica, California • Whittier, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

NCT01010061
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

NCT00250718
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Cancer
Interventions
Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 17, 2026, 2:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
51
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

NCT01998880
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

NCT00046683
View directory record Official record
Conditions
B Cell Chronic Lymphocytic Leukemia
Interventions
alemtuzumab
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT02100852
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
TGR-1202 + Obinutuzumab + Chlorambucil
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Huntsville, Alabama • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

NCT02612311
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ublituximab, TGR-1202, Chlorambucil
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

NCT02053610
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT02264574
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT00748189
View directory record Official record
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
chlorambucil, tablets, ofatumumab (GSK1841157) infusion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
30
States / cities
Sedona, Arizona • Tucson, Arizona • Murrieta, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

NCT00910910
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Chlorambucil
Drug
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
28
States / cities
Escondido, California • Whittier, California • New Britain, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 17, 2026, 2:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

NCT02242942
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Chlorambucil, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691
View directory record Official record
Conditions
Uveitis
Interventions
fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01868893
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 17, 2026, 2:30 PM EDT